Madrigal Pharmaceuticals Inc MDGL

US Biotechnology

$516.56 ▲ +0.65% (+$3.35)

Open $513.75

Prev Close $513.21

Day Range $511.31 – $523.96

52W Range $393.61 – $615.00

Market Cap $11.93B

Beta -1.09

EPS (TTM) $-12.87

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2007-02-06
Shares Out.	23,060,000
Website	madrigalpharma.com/ ↗
Phone	13026587581
Employees	915
Revenue	$364.3M
Gross Profit	$364.3M
Net Income	-$57.9M
Free Cash Flow	-$206.3M
Total Assets	$1.24B
Total Liabilities	$720.9M
Equity	$523.7M

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Inc is a publicly traded company under the ticker symbol MDGL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.